Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
I'm pretty sure you are correct about the mobile phone apps. Can you imagine the number of similar apps which charge next to nothing for monthly use that there are out there ? certainly a huge number and many of those have been around for sometime in one form or another. Hopefully there is money to be made by 3rd party companies that purchase licenses and the more fruitful maintenance contracts. Only time will tell of course, but I wont be holding my breath for any large income amounts. They may just make enough to pay for JG's salary, if that. Probably best to sell the whole thing on once its sorted together with the DLI employees.
Morning The.Italian,
It would be interesting to know what the commercial deal is. Are DLI paid each time it is used or is there some short-term (renewable) multiple user license agreement? I could be wrong, but, given there must be many apps which are touting for the same business, I cannot imagine there is at present much income.
The.Italian, certainly cannot argue with any of that. ;-)
Morning The.Italian,
Did you spot the deliberate mistake ? I wrote JG’s salary as pounds, but it should have been in USD., even so. Still excessive. :-)
Given it’s PLE who are sorting everything out, it does beg the huge question. What the fcuk does he do ???
That should have been “15 mins ago”. ;-)
To put into perspective….posted 15th s ago on the BBC News website.
Former Shell CEO Mr van Beurden's salary was £1.4m in 2022 and the company made a whacking 39bill squid for the same period (he moved on in Jan).
It certainly makes our CEOs salary package laughable (for JG that is). No profit since 2013 and a salary of 1.5mill squid. (Although that was reduced to 1 mill during the pandemic which I’m sure has gone back up).
Something to think about…..lol
Also interesting that PLE are the ones to file the dossier in China since I would have thought Wanbang would need to do it, unless its because it is outside China ? I wonder why China have not taken this opportunity to find their own manufacture ?
Morning The.Italian,
Interesting, but expected, although it did slip my mind. Any UK related approvals now have to have their own approvals (re the addition of a manufacturer). I would assume all other things approved before Brexit are automatically approved with no change.
Morning The.Italian,
Although the FDA process is ticking along, there still seems to be a lot of incompetence given their previous announcements.
According to the June 6th/22 Update....
After incorporating the FDA’s suggestions and recommendations into the Phase 3 protocol, the Company’s clinical research organisation has also completed the Phase 3 Study protocol, together with a ‘Type C’ meeting request, with the FDA for the product development of Fortacin. This meeting between the Company and the FDA should occur by mid to late September 2022 (being within 75 days of receipt by the FDA of the meeting request). We are hopeful that after providing a fulsome reply to the FDA’s advice and request letter and incorporating the FDA’s recommendations and suggestions into the Phase 3 study protocol, that the Company can proceed with its Phase 3 study shortly after the ‘Type C’ meeting.
Yet, they now state that the Type C meeting request wasn't made until Dec. No explanation has been given as to why their request for a meeting was refused, although there was some teleconf!!!
I also notice that they write that a clear NDA submission pathway has been agreed with the FDA, yet that agreement was already in place as announced in the PLE RNS 9983B. "Food and Drug Administration ("FDA") has now unambiguously defined the path to a successful submission of the New Drug Application"
As I wrote previously, given how long they have taken with the phase II, I really don't expect FDA approval till late 2025, if not 2026, which is incredible after they stated they would have approval by June 2017 in the first place (June 2018 with the extra 12 months for the 6 dose can debacle) . It certainly calls into question who is making it up...the FDA (I doubt) or our management.
I think everything now relies on China, which, I am sure will progress on schedule. They certainly make ERP's efforts laughable (and it even started 3 years after the US and that's allowing for a years delay because our lot hadn't checked the Chinese authorities had the necessary approval paperwork for the drugs used).
Anyway, it will be interesting to see how things progress with Recordati as there are no more excuses. And of course no more mention of PSNW who I guess have been sent packing with their tails between there legs.
They need to sort a license agreement this year otherwise it'll be further dilution (if Recordati don't sell many cans)
Certainly could have included a lot of the information in the prospectus. And there appears to be no mention of import license approval for Singapore last June.
All ticking along nicely, albeit slowly wrt FDA approval process. China, however, seems to be doing well and looks like will pass the finishing post first.
Or even jumbo jet hangers……..lol
Those are called industrial storage units :-O
;-)
Although a shed load for us minions, it’s only a thimble full for JM…..lol
Exactly ;-)
Yes, certainly will be an update at some point in time, although I don’t understand why nothing has been forthcoming. Even more strange that nothing was included in the recent prospectus to encourage investors to take up their rights, which, as I mentioned before, was probably intentional so Jim could get a larger slice of the cake, given the expected news this year…. ;-) Could be a good sign though ;-)
Morning The.Italian,
We were certainly lucky this purchase never went ahead (15mill USD now down to 1mill), although it does follow ERP's ability to invest and increase shareholder value....lol. Discussed before, but I do keep an eye on it out of interest given the hype JG gave in the media regarding the upward trajectory of the CBD market.
Seems Yooya is having problems and has decided to pull out of Japan (remember it was touted by the company as being Asia’s second largest ecommerce market in dollar terms !!!)
https://ca.finance.yahoo.com/news/yooma-announces-operational-updates-221500564.html
It would seem the CBD arena is on a slow downward spiral and SEED is being dragged down with it.
Thats effectively 3 investments that are complete disasters......DBC, Yooma and of course the current DLI which is still costing the company (shareholders) money.
Dougie,
Because it suffers from Narcissistic sour grapes syndrome.
Narcissistic personality disorder is a mental health condition in which people have an unreasonably high sense of their own importance. They need and seek much attention and want people to admire them. People with this disorder may lack the ability to understand or care about the feelings of others. But behind this mask of extreme confidence, they are not sure of their self-worth and are easily upset by the slightest criticism...
Sour grapes refers to an attitude in which someone adopts a negative attitude to something because they cannot have it themselves (ie, they were sacked as CEO a long long long long time ago).... Something most common in small children and babies'.....lol
Et voila !!!
Dougie,
I wouldn’t pay any attention to the ex Ple ceo since it has only one agenda and has been proven on many occasions to write utter carp in the hopes to discombobulate… :-) Best filtered and forgotten.